Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MGD024 |
Synonyms | |
Therapy Description |
MGD024 is a dual-affinity re-targeting (DART) molecule that targets both CD123 and CD3, which potentially leads to killing of tumor cells expressing CD123 and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 1165). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MGD024 | MGD-024|MGD 024 | MGD024 is a dual-affinity re-targeting (DART) molecule that targets both CD123 and CD3, which potentially leads to killing of tumor cells expressing CD123 and inhibition of tumor growth (Blood (2021) 138 (Supplement 1): 1165). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05362773 | Phase I | MGD024 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |